Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion type Assertion NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_head.
- NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion wasGeneratedBy ECO_0000203 NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_provenance.
- NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion wasDerivedFrom befree-20140225 NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_provenance.
- NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion SIO_000772 15195927 NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_provenance.
- NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion evidence source_evidence_literature NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_provenance.
- NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_assertion description "[One area of gene therapy that has generated much debate and controversy is the use of vascular endothelial growth factor (VEGF) for therapeutic angiogenesis for palliative intent, and for the prevention of restenosis following percutaneous revascularization in coronary and peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP227803.RAkOc-D42le3LWVxNF2MykhZ4JEFFH8JoF-rRRS4clTzk130_provenance.